PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA
Clinical trials for PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC